This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Pamiparib
- DrugBank Accession Number
- DB14769
- Background
Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Pamiparib (DB14769)
- Weight
- Average: 298.321
Monoisotopic: 298.122989282 - Chemical Formula
- C16H15FN4O
- Synonyms
- Pamiparib
- External IDs
- BGB-290
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- ATC Codes
- L01XK06 — Pamiparib
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8375F9S90C
- CAS number
- 1446261-44-4
- InChI Key
- DENYZIUJOTUUNY-MRXNPFEDSA-N
- InChI
- InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1
- IUPAC Name
- (2R)-14-fluoro-2-methyl-6,9,10,19-tetraazapentacyclo[14.2.1.0^{2,6}.0^{8,18}.0^{12,17}]nonadeca-1(18),8,12(17),13,15-pentaen-11-one
- SMILES
- C[C@]12CCCN1CC1=NNC(=O)C3=C4C(NC2=C14)=CC(F)=C3
References
- General References
- Not Available
- External Links
- ChemSpider
- 58805610
- ChEMBL
- CHEMBL4112930
- ZINC
- ZINC000150196116
- PDBe Ligand
- DS9
- PDB Entries
- 7cmw
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Ovarian Cancer 1 3 Enrolling by Invitation Treatment Advanced Malignant Neoplasm 1 3 Not Yet Recruiting Treatment Ovarian Cancer 1 2 Completed Treatment Advanced or Inoperable Gastric Cancer 1 2 Completed Treatment Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1 2 Not Yet Recruiting Treatment Ovarian Cancer 2 2 Recruiting Treatment Cancer 1 2 Recruiting Treatment Epithelial Ovarian Cancer 1 2 Recruiting Treatment Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 2 Recruiting Treatment Neoadjuvant Therapies 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0933 mg/mL ALOGPS logP 2.03 ALOGPS logP 1.39 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 10.28 Chemaxon pKa (Strongest Basic) 5.62 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 60.49 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 81.01 m3·mol-1 Chemaxon Polarizability 29.89 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 14:26 / Updated at February 21, 2021 18:54